Cytotoxic Drug Articles & Analysis
31 articles found
Antibody-Drug Conjugates (ADCs) represent a groundbreaking advancement in targeted cancer therapy, combining the specificity of antibodies with the potency of cytotoxic drugs. ...
Most of the old drugs are currently limited in their effectiveness because of poor pharmacokinetics, simple clearance by the body and cytotoxicity. Nanoparticle technology in particular, Nano drug delivery system is getting a lot of attention and application in medicine in the recent years. ...
Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). These advancements not only enhance our understanding of the disease but also pave the way for more targeted therapeutic solutions. ...
Antibody-drug conjugates (ADCs) represent a groundbreaking class of therapeutics that combine the specificity of monoclonal antibodies (mAbs) with the potent cytotoxic effects of small-molecule drugs. ...
Introduction In the ever-evolving landscape of drug delivery systems, nanoformulation stands out as a revolutionary approach. ...
ADCs are complex molecules composed of an antibody linked to a biologically active cytotoxic or radioactive compound. They combine the specificity of antibodies, which enables specific target cell binding, and the cell-killing activity of cytotoxic drugs, providing a method of delivering these agents directly to cancer cells. ...
With the approval of many antibody-drug conjugation (ADC) drugs around the world since 2019, conjugate drugs have developed into one of the hottest tracks in the pharmaceutical industry. ...
In order to more effectively deliver chemotherapy drugs, Small Molecule Drug Conjugates (SMDC), Antibody Drug Conjugates (ADC), and Degradation Antibody Conjugates (DAC) have been successively explored and developed, enhancing the therapeutic index while providing selective delivery. ...
Biopharma PEG, a leading innovator in polyethylene glycol (PEG) derivatives, proudly introduces its featured Azide PEG series, which can be used in drug development, click chemistry, ADCs (Antibody Drug Conjugates), PROTACs (Proteolysis Targeting Chimeras), and beyond. ...
Antibody drug conjugates (ADCs) are a new class of biopharmaceuticals that use monoclonal antibodies to target tumor cells to deliver potent cytotoxic drugs. ...
The NIR-PIT drug is not a cytotoxic substance, but a water-soluble phthalocyanine derivative.Dual Payload ADCAs resistance to ADC therapies emerges, combining one antibody with two or more different cytotoxic payloads provides options for the development of next-generation ADCs. ...
This article aims to provide an overview of different bioconjugation strategies employed for various drug classes, highlighting their advantages, challenges, and potential applications Bioconjugation involves the covalent linkage of drugs or drug carriers to biological macromolecules, thereby enhancing their stability, solubility, and ...
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ...
Average drug-to-antibody ratio (DAR) and drug load distribution are two vital properties of antibody drug conjugates (ADCs). ...
Improve ADC production In recent years, scientists have developed a new class of targeted drugs - antibody-drug conjugate (ADC). In the first generation of ADCs, the traditional coupling reaction is used, and it is not possible to control how many cytotoxic drug molecules bind to amino acid residues in monoclonal antibodies, nor ...
They combine the high specificity of monoclonal antibody drugs with the high activity of small molecule cytotoxic drugs, which can improve the targeting of antitumor drugs and reduce the probability of toxic and side effects. ...
Structurally, an ADC consists of monoclonal antibodies (Antibody) that target specific antigens on tumor surfaces, cytotoxic drugs (drugs) that kill tumor cells, and linkers (Conjugate/ linkers) that conjugate cytotoxic drugs to antibodies. ...
Drug-to-antibody ratio (DAR, drug-to-antibody ratio) The number of cytotoxic drugs connected to each antibody is the drug-to-antibody ratio (DAR). When the DAR increases, the drug metabolism rate of ADC drugs increases, the half-life decreases, and the systemic toxicity ...
At present, ADC drugs use humanized monoclonal antibodies to modify the Fc fragment to enhance its ADCC (antibody-dependent cell-mediated cytotoxicity) effects and CDC (complement-dependent cytotoxicity) effects. At present, ADC drugs mostly use IgG1 molecules in humanized monoclonal antibody subtypes. ...
Dertrastuzumab is an antibody-drug conjugate (ADC) drug consisting of a humanized monoclonal antibody targeting HER2 attached to a topoisomerase 1 inhibitor payload via a tetrapeptide cleavable linker. ...